NEUROCRINE BIOSCIENCES INC Restricted Cash and Cash Equivalents, Noncurrent
NEUROCRINE BIOSCIENCES INC (NBIX) had Restricted Cash and Cash Equivalents, Noncurrent of $8.00 million as of 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2023-08-01
- 2023-06-30: Restricted Cash and Cash Equivalents, Noncurrent $8.00M.
- 2023-03-31: Restricted Cash and Cash Equivalents, Noncurrent $7.80M.
- 2022-12-31: Restricted Cash and Cash Equivalents, Noncurrent $7.80M.
- 2022-09-30: Restricted Cash and Cash Equivalents, Noncurrent $7.80M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent | Restricted Cash and Cash Equivalents, Noncurrent as first filed |
|---|---|---|
| 2023-06-30 | $8.00M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $7.80M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $7.80M 10-K · filed 2023-02-09 | |
| 2022-09-30 | $7.80M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $7.80M 10-Q · filed 2023-08-01 | |
| 2022-03-31 | $7.80M 10-Q · filed 2023-05-03 | |
| 2021-12-31 | $3.20M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $3.20M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $3.20M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $3.20M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $3.20M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $3.20M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $3.20M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $3.20M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $3.20M 10-K · filed 2021-02-05 | $3.21M 10-K · filed 2020-02-07 |
| 2019-09-30 | $4.71M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $5.48M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $5.48M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $5.48M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $5.48M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $5.48M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $4.50M 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $4.50M 10-K · filed 2019-02-08 | |
| 2017-09-30 | $4.61M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $4.61M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $5.08M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $4.88M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $4.88M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $4.88M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $4.99M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $4.79M 10-K · filed 2017-02-14 | |
| 2015-09-30 | $4.79M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $4.82M 10-Q · filed 2015-07-29 | |
| 2015-03-31 | $4.83M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $4.83M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $4.44M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $4.44M 10-Q · filed 2014-08-06 | |
| 2014-03-31 | $4.44M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $4.44M 10-K · filed 2015-02-09 | |
| 2013-09-30 | $4.33M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $4.33M 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $4.33M 10-Q · filed 2013-05-02 | |
| 2012-12-31 | $4.33M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $4.33M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $4.33M 10-Q · filed 2012-07-31 | |
| 2012-03-31 | $4.31M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $4.31M 10-K · filed 2013-02-08 | |
| 2011-09-30 | $6.13M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $6.10M 10-Q · filed 2011-07-29 | |
| 2010-12-31 | $6.10M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |